Trials / Completed
CompletedNCT02413346
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 490 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sarecycline | Administered based on participant's body weight. |
Timeline
- Start date
- 2015-03-20
- Primary completion
- 2016-08-26
- Completion
- 2016-08-26
- First posted
- 2015-04-09
- Last updated
- 2019-02-01
- Results posted
- 2018-05-04
Locations
56 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02413346. Inclusion in this directory is not an endorsement.